Last reviewed 2026-04-22 · How we verify

Angal, lozenges [menthol],

Sandoz · Phase 3 active Small molecule

Angal, lozenges [menthol], is a Topical analgesic/local anesthetic Small molecule drug developed by Sandoz. It is currently in Phase 3 development for Sore throat pain and irritation, Cough suppression.

Menthol provides local anesthetic and cooling sensations to soothe throat irritation and cough.

Menthol provides local anesthetic and cooling sensations to soothe throat irritation and cough. Used for Sore throat pain and irritation, Cough suppression.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Angal, lozenges [menthol],
Sponsor	Sandoz
Drug class	Topical analgesic/local anesthetic
Target	TRPM8 receptor
Modality	Small molecule
Therapeutic area	Respiratory/Otolaryngology
Phase	Phase 3

Mechanism of action

Menthol is a naturally occurring compound that activates TRPM8 cold receptors on sensory nerve endings, producing a cooling sensation that numbs minor throat pain and irritation. This local anesthetic effect, combined with mild antimicrobial properties, helps suppress cough reflex and provide symptomatic relief of sore throat discomfort.

Approved indications

Sore throat pain and irritation
Cough suppression

Common side effects

Local irritation or burning sensation
Allergic reaction (rare)

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Angal, lozenges [menthol], CI brief — competitive landscape report
Angal, lozenges [menthol], updates RSS · CI watch RSS
Sandoz portfolio CI

Frequently asked questions about Angal, lozenges [menthol],

What is Angal, lozenges [menthol],?

Angal, lozenges [menthol], is a Topical analgesic/local anesthetic drug developed by Sandoz, indicated for Sore throat pain and irritation, Cough suppression.

How does Angal, lozenges [menthol], work?

Menthol provides local anesthetic and cooling sensations to soothe throat irritation and cough.

What is Angal, lozenges [menthol], used for?

Angal, lozenges [menthol], is indicated for Sore throat pain and irritation, Cough suppression.

Who makes Angal, lozenges [menthol],?

Angal, lozenges [menthol], is developed by Sandoz (see full Sandoz pipeline at /company/sandoz).

What drug class is Angal, lozenges [menthol], in?

Angal, lozenges [menthol], belongs to the Topical analgesic/local anesthetic class. See all Topical analgesic/local anesthetic drugs at /class/topical-analgesic-local-anesthetic.

What development phase is Angal, lozenges [menthol], in?

Angal, lozenges [menthol], is in Phase 3.

What are the side effects of Angal, lozenges [menthol],?

Common side effects of Angal, lozenges [menthol], include Local irritation or burning sensation, Allergic reaction (rare).

What does Angal, lozenges [menthol], target?

Angal, lozenges [menthol], targets TRPM8 receptor and is a Topical analgesic/local anesthetic.

Drug class: All Topical analgesic/local anesthetic drugs
Target: All drugs targeting TRPM8 receptor
Manufacturer: Sandoz — full pipeline
Therapeutic area: All drugs in Respiratory/Otolaryngology
Indication: Drugs for Sore throat pain and irritation
Indication: Drugs for Cough suppression

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing